Shanghai Rendu Biotechnology Co., Ltd. (SHA:688193)
China · Delayed Price · Currency is CNY 52.10
-1.42 (-2.65%)
At close: Jun 12, 2026
SHA:688193 Revenue
Shanghai Rendu Biotechnology had revenue of 42.08M CNY in the quarter ending March 31, 2026, with 3.43% growth. This brings the company's revenue in the last twelve months to 163.46M, down -5.64% year-over-year. In the year 2025, Shanghai Rendu Biotechnology had annual revenue of 161.94M, down -8.69%.
Revenue (ttm)
163.46M
Revenue Growth
-5.64%
P/S Ratio
12.36
Revenue / Employee
487.93K
Employees
290
Market Cap
2.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 161.94M | -15.41M | -8.69% |
| Dec 31, 2024 | 177.35M | 12.94M | 7.87% |
| Dec 31, 2023 | 164.41M | -139.44M | -45.89% |
| Dec 31, 2022 | 303.85M | 11.54M | 3.95% |
| Dec 31, 2021 | 292.31M | 42.40M | 16.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Runda Medical Technology | 6.85B |
| Maccura Biotechnology Co.Ltd | 2.14B |
| Medicalsystem Biotechnology | 1.54B |
| Shanghai Labway Clinical Laboratory | 1.38B |
| Amoy Diagnostics | 1.19B |
| Thalys Medical Technology Group | 971.32M |
| Berry Genomics Co.,Ltd | 922.27M |
| SMO ClinPlus CO.,LTD. | 860.07M |